Market Analysis - Monthly Report - September&October, 2020 - Remdesivir

Annual Report - September, 2020

Overview of the Current Market Situation

The price of Remdesivir dropped in September. With the prolonged spread of the epidemic, specific drugs and new drug combination treatment programs have become increasingly perfect. Vaccines have also made great progress in the development stage. Due to the early stage of the spread of the epidemic, many well-known foreign pharmaceutical manufacturers invested a lot of money in the research and development and production of Redecive, resulting in overcapacity at present, so the price of Redecive is declining. In China, many pharmaceutical R&D companies withdrew from the R&D work of Redcivir. Although their synthesis technology is relatively mature, they have lost their competitiveness under the current market conditions. In China, the industrial chain of upstream pharmaceutical intermediates of remdesivir is relatively sound and has technological advantages. On the demand side, due to the continuous spread of the epidemic, the global demand for Redecive continues. One reason for the price drop in September was due to increased global production.

 Forecast of the Future Market Situation

The overall market situation in October was similar to that in September. The industry will tend to be centralized, and market inventory will be emptied. Therefore, by then, if the epidemic continues to spread, the price of Remdesivir will also have an upward trend. Overall, the epidemic will not disappear or abate in October. With the advent of autumn and winter, it is impossible to predict whether this epidemic will intensify. However, there are questions about the effectiveness of Remdesivir in treating the epidemic.

Annual Report - October, 2020

 Overview of the Current Market Situation

In October, the price of Remdesivir dropped. Although this epidemic continues to spread around the world, many well-known foreign pharmaceutical manufacturers have invested in its research and development and production, and there is also a trend to expand the scale of production. However, in early October, official sources reported that Remdesivir was ineffective in treating the epidemic. Almost all global R&D projects on Remdesivir have been suspended, awaiting further official reports. In China, the industrial chain of upstream pharmaceutical intermediates of Remdesivir is relatively sound and has technological advantages. However, the research and development work for Remdesivir has been ongoing. In terms of demand, as the epidemic continues to spread, the demand for Remdesivir should have been on the rise, but because of the denial of official reports, the market has entered a cold period. The price drop in October was due to official reports.

 Forecast of the Future Market Situation

In November, the market trend of Remdesivir was not clear. If there is no official agency to prove that Remdesivir is effective against the epidemic, the market situation of Remdesivir will remain sluggish.